



## **CorePharma and GlaxoSmithKline conclude agreement on US rights for Dexedrine<sup>®</sup>, Albenza<sup>®</sup> and Daraprim<sup>®</sup>**

### **- CorePharma also obtains rights to Daraprim in Canada**

MIDDLESEX, NJ, RESEARCH TRIANGLE PARK, NC (October 22, 2010) - CorePharma, LLC, and GlaxoSmithKline, PLC, today announced an agreement under which CorePharma will acquire the U.S. NDAs for Dexedrine<sup>®</sup> (dextroamphetamine sulfate) SPANSULE<sup>®</sup> sustained-release capsules, Albenza<sup>®</sup> (albendazole) tablets, and Daraprim<sup>®</sup> (pyrimethamine) tablets in the United States and Puerto Rico. GSK will retain the existing rights for these products in countries outside the United States, except for Daraprim in Canada, where rights will also be divested to CorePharma. CorePharma's new subsidiary, Amedra Pharmaceuticals, will market these brands in the U.S.

Terms of the agreement have not been disclosed.

"The acquisition of these products will play an important strategic role in our growth," stated Christopher Worrell, Chief Executive Officer of CorePharma. "The organizational strengths that we have developed at CorePharma will provide an excellent foundation for our efforts with our new subsidiary, Amedra. Our joint capabilities, with CorePharma in generics and Amedra Pharmaceuticals in branded products, will be pivotal to our future success."

This agreement will not affect GSK's ongoing commitment to supply the WHO with 600 million tablets of albendazole per year for use in the Global Programme to Eliminate Lymphatic Filariasis. In the short-term, GSK will be responsible for the supply of Albenza to CorePharma and will be also involved in the Daraprim supply chain. Dexedrine is manufactured by third party suppliers who will continue to supply CorePharma.

The agreement is not subject to Hart-Scott-Rodino regulatory clearance in the United States.

**GlaxoSmithKline** – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information go to [us.gsk.com](http://us.gsk.com), follow us on [twitter.com/GSKUS](https://twitter.com/GSKUS) or visit our [blog \(www.morethanmedicine.us.gsk.com/blog/\)](http://www.morethanmedicine.us.gsk.com/blog/).

**CorePharma, LLC** — CorePharma manufactures and markets high-quality, targeted, prescription pharmaceuticals. CorePharma's current product line covers nearly three dozen offerings. The company produces over a billion tablets and capsules annually in its facilities. All of CorePharma's facilities are located in Middlesex, New Jersey. CorePharma continually invests in its manufacturing, packaging and testing facilities to bolster efficiencies, maintain quality, add capacity and enhance technologies. For further information please visit [www.corepharma.com](http://www.corepharma.com).